The differences of asymmetric dimethylarginine removal by different dialysis treatments

Renal Failure

Volumn 32, Issue 8, 2010, Pages 935-940

  Zhang, Dong Liang ^a   Liu, Jing ^a   Liu, Sha ^a   Zhang, Yu ^a   Liu, Wen Hu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine; Hemodiafiltration; Hemodialysis; Peritoneal dialysis

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; BLOOD LEVEL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESIDUAL URINE; URINARY EXCRETION; URINE LEVEL; URINE VOLUME;

ADULT; AGE FACTORS; AGED; ARGININE; DIALYSIS SOLUTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS;

EID: 77955937773     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.502281     Document Type: Article

References (23)

1. Morris STW, Mcmurray JJV, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001;60:1077-1082.
2. Flecka C, Schweitzera F, Kargea E, et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clinica Chimica Acta. 2003;336:1-12.
3. Morris ST, McMurray J, Rodger R, et al. Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant. 2000;15:1194-1200.
4. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal-failure associated endothelial dysfunction. Kidney Int. 1998;53:1068-1077.
5. Kari JA, Donald AE, Vallance DT, et al. Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468-472.
6. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449-2455.
7. Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008;31:747-752.
8. Zoccali C, Bode B, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358:2113-2117.
9. Lu TM, Ding YA, Lin SJ, et al. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24: 1912-1919.
10. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene study. Circ Res. 2005;97:53-59.
11. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-2128.
12. Schulzc F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the influnce of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.
13. Chaytan C, Gupta B, Meindel N, et al. Fractional directi dialysis quantification: A new approach for prescription and monitoring hemodialysis therapy. Kidney Int. 1996;50(6):1845-1849.
14. Russell CD, Bischoff PG, Kontzen FN, et al. Measurement of glomerular filtration rate: Single injection plasma clearance method without urine collection. J Nucl Med. 1985;26(11):1243-1247.
15. Anderstam B, Katzatski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437-1442.
16. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594-600.
17. Kielstein JT, Böger RH, Bode-Böger SM, et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. Clin. Nephrol. 2004;62(4):295-300.
18. Panichi V, Mantuano E, Paoletti S, et al. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008;21:38-44.
19. Wahbi N, Dalton RN, Turner C, et al. Dimethylarginines in chronic renal failure. J Clin Pathol. 2001;54:470-473.
20. Böger RH, Zoccali C. ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis Suppl. 2003;4:23-28.
21. Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10(Suppl. 1):S73-S81.
22. Carello KA, Whitesall SE, Lloyd MC, et al. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol. 2006;290:H209-H216.
23. Ebinç FA, Erten Y, Ebinç H, et al. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients. Renal Failure. 2008;30:401-406.